Anika Therapeutics (NASDAQ: ANIK) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.
Valuation and Earnings
This table compares Anika Therapeutics and Myovant Sciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Anika Therapeutics||$103.38 million||8.37||$32.54 million||$2.13||27.71|
|Myovant Sciences||N/A||N/A||-$83.44 million||($1.41)||-9.57|
Volatility & Risk
Anika Therapeutics has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of -2.08, indicating that its stock price is 308% less volatile than the S&P 500.
This table compares Anika Therapeutics and Myovant Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Anika Therapeutics and Myovant Sciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Anika Therapeutics presently has a consensus price target of $57.00, indicating a potential downside of 3.44%. Myovant Sciences has a consensus price target of $22.50, indicating a potential upside of 66.67%. Given Myovant Sciences’ higher possible upside, analysts clearly believe Myovant Sciences is more favorable than Anika Therapeutics.
Insider & Institutional Ownership
84.9% of Anika Therapeutics shares are held by institutional investors. Comparatively, 79.2% of Myovant Sciences shares are held by institutional investors. 6.6% of Anika Therapeutics shares are held by company insiders. Comparatively, 2.8% of Myovant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Anika Therapeutics beats Myovant Sciences on 9 of the 11 factors compared between the two stocks.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.